7 days ago by Neuschwanstein

Gene-screening has been used to identify women most likely to benefit from one type of breast cancer chemotherapy. The technique could lead to a simple test enabling doctors to administer personalised treatment, say researchers. In future the same method may offer a way of predicting which patients ...

Lancastria.net Yea Blackburn! - lancastria.net/blog · 6 references

17 days ago

Condition: Malignant Solid Tumour Interventions: Biological: ramucirumab (IMC1121B); Drug: paclitaxel Sponsor: ImClone LLC Not yet recruiting – verified January 2012 Read more from the original source: A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors

Cancer News - Cancernewsdigest.com · Rank: 109,542

22 days ago

Condition: Metastatic Breast Cancer Interventions: Drug: U3-1287; Drug: Trastuzumab; Drug: Paclitaxel; Drug: U3-1287; Drug: Trastuzumab; Drug: Paclitaxel; Drug: Placebo Sponsors: Daiichi Sankyo Inc.; ACTIVA Recruiting – verified January 2012 Continue reading here: Phase 1b/2 Study of U3-1287 in Comb ...

Cancer News - Cancernewsdigest.com · Rank: 109,542

64 days ago by akampion

- Positive efficacy trend of EndoTAG®-1/Paclitaxel combination therapy confirmed - Subgroup analysis reveals encouraging overall survival data with EndoTAG®-1 plus paclitaxel combination therapy MediGene AG today announced median overall survival data from its phase II trial of EndoTAG®-1 for the tr ...

the akampioneer - akampioneer.com · 3 references

73 days ago by Redactia

Oamenii de stiinta francezi au descoperit pentru cazurile de cancer ovarian doua caracteristici genetice care permit identificarea tumorilor agresive si a reactiilor acestora la tratament, potrivit unui studiu publicat in revista Nature Medicine. Un nou tratament pentru cancerul ovarian Aceasta desc ...

Stiri online - Ziare online - newspapertimes.ro · Rank: 96,827 · 1 reference

80 days ago by deniedclaim

FDA Commissioner Margaret Hamburg is revoking the agency’s accelerated approval of the breast cancer indication for Avastin (bevacizumab), manufactured by Genentech. Avastin used for metastatic breast cancer has not been shown to provide a benefit, in terms of delay in the growth of tumors, that wou ...

Denied Claim Blog - deniedclaim.wordpress.com

84 days ago by admin

FRIDAY, Nov. 18 (HealthDay News) — Saying tһе risks transcend tһе benefits іח patients wіtһ modernized breast cancer, U.S. Food аחԁ Drug Administration Commissioner Dr. Margaret Hamburg ѕаіԁ οח Friday tһаt ...

Life After Breast Cancer - lifeafterbreastcancer.org

84 days ago by Paul Cacciatore

Today, the U.S. Food and Drug Administration (FDA) Commissioner Hamburg revoked approval of Avastin for treatment of metastatic breast cancer in the U.S. The decision does not impact Avastin’s availability for its approved uses for other cancer types in the U.S. A major U.S. ovarian cancer advocacy ...

Libby's H*O*P*E* - healthinfoispower.wordpress.com · 24 references

84 days ago by Great Speculations: Nigam Arora

[1]FDA Commissioner Hamburg The best selling cancer drug in the world for breast cancer is Avastin. The U.S. Food and Drug Administration (FDA) has just announced that Avastin is no longer an approved drug to treat metastatic breast cancer. Avastin was developed by Genentech, which was acquired by R ...

Forbes Network Activity - blogs.forbes.com/network/rss · Rank: 35,306

107 days ago by Ed Silverman

As the FDA ponders its controversial move to yank the breast cancer indication for Avastin, a new survey shows that doctors are largely split over whether they will continue to favor the medication for this use. Nearly 45 percent would use Avastin in a first-line setting and nearly 52 percent would ...

Pharmalot - pharmalot.com · Rank: 2,230 · 709 references